InSightec's MRgFUS system approved in Japan for treatment of women with uterine fibroids

Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today that it was informed by InSightec Ltd. ("InSightec") that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved InSightec's MR-guided Focused Ultrasound (MRgFUS) system for the treatment of pain palliation caused by bone metastases and advanced treatment for women with uterine fibroids. As a result, InSightec may expand its product portfolio for the Japanese market.

MHLW has also approved the advanced treatment for women with uterine fibroids. This advanced treatment provides additional treatment options and shortens treatment time, allowing physicians to better monitor the procedure.

GE Healthcare is the holder of the above mentioned approval and distributor of ExAblate in Japan.

The Company holds approximately 89% of the share capital of Elbit Medical Technologies Ltd. (TASE: EMTC-M) (on a fully diluted basis) which, in turn, holds approximately 37.6% of the share capital in InSightec (and 33.3% on a fully diluted basis).

SOURCE Elbit Imaging Ltd.